Mesenchymal Stromal Cells for Degenerative Meniscus Injury

A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02033525

Enrollment

Registered

2014-01-10

Start date

2014-01-31

Completion date

2017-05-02

Last updated

2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Meniscal Injury

Keywords

Chronic Meniscal Injury, Degenerative meniscus, Meniscus injury, Meniscal injury, Mesenchymal stromal cells, Mesenchymal stem cells, Advanced Therapy, Bone marrow

Brief summary

The present proposal has the objective to assess whether the addition of autologous ex vivo expanded mesenchymal stromal cells (XCEL-M-ALPHA) to the conventional meniscal injury rehabilitation program is contributing in creating the proper healing environment for the meniscus repair. For this purpose, 20 patients will be randomized (10 per group) to one of the two treatment arms (rehabilitation + xcel-m-alpha or rehabilitation alone) . The conduction of this clinical trial will, in addition of having the aim of improving the patient's quality of life, contribute to consolidate an emerging new type of therapy which is still under development.

Detailed description

This is a prospective, unicentric, randomized, open-label, single-dose, two-arm, blinded assessor pilot study in which 20 patients with degenerative meniscus injury grade 3 (Crues et al.) will enter the study with the primary objective of assessing the efficacy of the treatment by VAS of pain at 12 month. Secondary objectives are to evaluate the safety and efficacy through imaging procedures and clinical questionnaires (IKDC, KOOS, Lysholm and SF-36. Patients will be randomized to one of the two treatment arms (XCEL-M-ALPHA and standard rehabilitation program or standard rehabilitation program alone). Thereafter, patients will be followed for 12 months. Imaging assessment will be performed by an independent blinded radiologist.

Interventions

DRUGXCEL-M-ALPHA and standard rehabilitation

Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)

OTHERRehabilitation

Standard rehabilitation program

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patient between 40 and 60 years of age * Degenerative meniscus injury grade 3 (Crues et al.) * Indication of conservative treatment * Normal alignment of the knee (between 3º varus and 10 º valgus) * Patient is able to follow a rehabilitation program * Informed consent given by the patient in writing * Patient is able to understand the trial.

Exclusion criteria

* Traumatic meniscus injury * Surgical intervention to the affected knee * Local or systemic infection * Intraarticular treatment of the affected knee with steroids or hyaluronic acid within the past 3 months * Significant abnormal laboratory tests that contraindicates participation in the trial. * Pregnant women or intend to become pregnant or breast-feeding * Neoplastic process within the previous 5 years or without complete remission. * The patient is wearing a pacemaker, allergy to contrast, severe renal insufficiency or any other condition that contraindicates the magnetic resonance using contrast. * Other pathologic conditions or circumstances that difficult participation in the study according to medical criteria * Legally dependant patient. * The patient does not accept to be followed-up for a period that could exceed the clinical trial length

Design outcomes

Primary

Measure	Time frame	Description
VAS for pain	12 month	Visual analogue scale (VAS) for pain at 12 month follow-up.

Secondary

Measure	Time frame	Description
Safety	12 month	Safety will be assessed by collecting adverse events, physical exam, laboratory tests, and vital signs.
Efficacy by MRI	6 and 12 month	Efficacy will be assessed by qualitative and quantitative changes of the meniscus and articular cartilage by imaging procedures (MRI) at 6 and 12 month follow-up.
VAS for pain	1, 3 and 6 month	Visual analogue scale (VAS) for pain at 1, 3 and 6 month follow-up.
Efficacy by clinical questionnaires	3, 6 and 12 month	IKDC, KOOS and Lysholm functionality test and SF-36 quality of life at 3, 6 and 12 month follow-up

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026